Postmenopausal osteoporosis
Conditions
Interventions
Alendronate Group:Alendronate 70mg/week orally
Zoledronic acid :Zoledronic acid 5mg/year intravenously
Sponsors
The First Affiliated Hospital of Xi 'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Women's natural menopause time >= 2 years; 2. In line with the 2020 AACE/ACE "Diagnosis and Treatment of Postmenopausal Osteoporosis" guidelines, all patients have undergone dual-energy X-ray absorptiometry to determine the lumbar spine (front and back), femoral neck, total hip joint or distal radius 1 3 Bone mineral density T value <=2.5.
Exclusion criteria
Exclusion criteria: 1. Long-term use of glucocorticoids; 2. Use bisphosphonates, calcitonin and other drugs that affect bone metabolism within 1 year before enrollment; 3. Suffer from diseases that affect bone metabolism, such as diabetes, multiple myeloma, rheumatic diseases, thyroid and parathyroid diseases, etc.; 4. Patients with tumors and abnormal immune function; 5. Severe pathological changes in important organs such as heart, liver, kidney and brain, including: estimated eGFR < 35mL /min, liver cirrhosis, etc.; 6. Patients with mental disorders who do not cooperate with treatment; 7. Patients who are allergic to the test drug; 8. Patients who are contraindicated with the test drug: patients with hypocalcemia, pregnant women, breastfeeding women, esophageal abnormalities that cause delay in emptying of the embassy, such as esophageal stenosis, patients who cannot stand or sit upright for at least 30 minutes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total hip joint T value;Bone trabecular fraction of Lumbar spine;N-terminal propeptide of type I procollagen;ß cross-linked C-telopeptide of type 1 collagen; | — |
Countries
China
Contacts
Public ContactCui Wei
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed